FDA Clears Roche Respiratory Panel with Expanded Pathogen Coverage
New cobas eplex RP3 panel detects up to 19 respiratory pathogens, including Bordetella pertussis, with results available in under two hours.
New cobas eplex RP3 panel detects up to 19 respiratory pathogens, including Bordetella pertussis, with results available in under two hours.
The FDA has granted a CLIA waiver for FebriDx, enabling its use in over 300,000 U.S. point-of-care settings and potentially reaching 80 million patients annually, according to PHASE Scientific.
The company aims to support FDA 510(k) clearance submission for its point-of-care platform detecting flu A/B, COVID-19, and RSV.
QIAGEN’s QIAstat-Dx Respiratory Panel Mini provides fast and accurate diagnosis of upper respiratory infections in outpatient settings.
Read MoreRoche introduced the cobas Respiratory flex test which uses TAGS technology to identify up to 15 pathogens in a single PCR test.
Read MoreA blood test predicts the likelihood of adults developing severe respiratory diseases by analyzing proteins linked to lung function decline.
Read MoreSaliva tests more accurately indicate the severity of recurrent respiratory infections in children compared to standard blood tests.
Read MoreResearchers developed a smartphone-controlled centrifugal microfluidic device that rapidly detects different subtypes of the influenza virus.
Read MoreResearchers developed a paper strip test using CRISPR technology that can quickly and accurately diagnose various influenza strains.
Read MoreRoche’s cobas liat COVID, Influenza A/B & RSV test, is a rapid RT-PCR assay that detects multiple respiratory viruses from a single sample.
Read MoreResearchers have developed an advanced electrostatic air sampler that enhances rapid detection of airborne influenza and coronavirus.
Read MoreQIAGEN’s QIAstat-Dx Respiratory Panel Plus, a syndromic testing tool for diagnosing respiratory infections, received FDA clearance.
Read MoreADLM’s new guidance on clinical testing for respiratory viral infections emphasizes the use of advanced diagnostic methods and sample types.
Read MoreResearchers demonstrated that metal-enhanced fluorescence probes could rapidly detect influenza virus proteins without complex lab equipment.
Read MoreEvidation has been awarded a contract by BARDA to fund the 2023 Influenza-like Illness (ILI) Detect & Protect Studies.
Read MoreA parallel test developed by Karius aims to improve treatment for serious diseases by diagnosing infections more rapidly and effectively.
Read MoreThe new biochip offers the potential to test multiple pathogens responsible for respiratory infections, such as COVID, RSV, and influenza.
Read MoreNew data provides a unique snapshot of the interplay among SARS-CoV-2, influenza, and respiratory syncytial virus (RSV).
Read More